| Barbara Lubovich, APN, CNM | |
|
4400 W 95th St Ste 207, Oak Lawn, IL 60453-2658 | |
| (708) 684-5340 | |
| (708) 684-3371 |
| Full Name | Barbara Lubovich |
|---|---|
| Gender | Female |
| Speciality | Certified Nurse Midwife (cnm) |
| Experience | 13 Years |
| Location | 4400 W 95th St Ste 207, Oak Lawn, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447524640 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | 209009050 (Illinois) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Advocate Health And Hospitals Corporation | 7810800935 | 2422 |
News Archive
Diabetes Hands Foundation (DHF) announced today that it is the recipient of two Telly Awards for the diabetes awareness video Big Blue Test.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today results from a long-term efficacy study of Glybera (alipogene tiparvovec) that showed improved chylomicron metabolism could be used as a biomarker for increased lipoprotein lipase (LPL) activity in those patients missing the gene that produces this protein.
Inovio Pharmaceuticals, Inc. announced today that in a preclinical study with two animal models, Inovio's hTERT (human telomerase reverse transcriptase) DNA cancer vaccine administered with Inovio's CELLECTRA adaptive electroporation delivery technology generated robust and broad immune responses, broke the immune system's tolerance to its self-antigens, induced T-cells with a tumor-killing function, and increased the rate of survival.
Isis Pharmaceuticals, Inc. today announced its financial results for the quarter ended June 30, 2010. The Company finished the second quarter of 2010 with a pro forma net operating loss (NOL) of $15.5 million and $17.1 million for the three and six months ended June 30, 2010, respectively, compared to a pro forma net operating loss of $1.3 million and pro forma net operating income of $798,000 for the same periods of 2009.
› Verified 7 days ago
| Entity Name | Advocate Health And Hospitals Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700824455 PECOS PAC ID: 7810800935 Enrollment ID: O20031106000064 |
News Archive
Diabetes Hands Foundation (DHF) announced today that it is the recipient of two Telly Awards for the diabetes awareness video Big Blue Test.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today results from a long-term efficacy study of Glybera (alipogene tiparvovec) that showed improved chylomicron metabolism could be used as a biomarker for increased lipoprotein lipase (LPL) activity in those patients missing the gene that produces this protein.
Inovio Pharmaceuticals, Inc. announced today that in a preclinical study with two animal models, Inovio's hTERT (human telomerase reverse transcriptase) DNA cancer vaccine administered with Inovio's CELLECTRA adaptive electroporation delivery technology generated robust and broad immune responses, broke the immune system's tolerance to its self-antigens, induced T-cells with a tumor-killing function, and increased the rate of survival.
Isis Pharmaceuticals, Inc. today announced its financial results for the quarter ended June 30, 2010. The Company finished the second quarter of 2010 with a pro forma net operating loss (NOL) of $15.5 million and $17.1 million for the three and six months ended June 30, 2010, respectively, compared to a pro forma net operating loss of $1.3 million and pro forma net operating income of $798,000 for the same periods of 2009.
› Verified 7 days ago
| Entity Name | The Board Of Trustees Of The University Of Illinois |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386863819 PECOS PAC ID: 3072422716 Enrollment ID: O20031112000158 |
News Archive
Diabetes Hands Foundation (DHF) announced today that it is the recipient of two Telly Awards for the diabetes awareness video Big Blue Test.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today results from a long-term efficacy study of Glybera (alipogene tiparvovec) that showed improved chylomicron metabolism could be used as a biomarker for increased lipoprotein lipase (LPL) activity in those patients missing the gene that produces this protein.
Inovio Pharmaceuticals, Inc. announced today that in a preclinical study with two animal models, Inovio's hTERT (human telomerase reverse transcriptase) DNA cancer vaccine administered with Inovio's CELLECTRA adaptive electroporation delivery technology generated robust and broad immune responses, broke the immune system's tolerance to its self-antigens, induced T-cells with a tumor-killing function, and increased the rate of survival.
Isis Pharmaceuticals, Inc. today announced its financial results for the quarter ended June 30, 2010. The Company finished the second quarter of 2010 with a pro forma net operating loss (NOL) of $15.5 million and $17.1 million for the three and six months ended June 30, 2010, respectively, compared to a pro forma net operating loss of $1.3 million and pro forma net operating income of $798,000 for the same periods of 2009.
› Verified 7 days ago
| Entity Name | The Board Of Trustees Of The University Of Illinois |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154541936 PECOS PAC ID: 3072422716 Enrollment ID: O20031201000021 |
News Archive
Diabetes Hands Foundation (DHF) announced today that it is the recipient of two Telly Awards for the diabetes awareness video Big Blue Test.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today results from a long-term efficacy study of Glybera (alipogene tiparvovec) that showed improved chylomicron metabolism could be used as a biomarker for increased lipoprotein lipase (LPL) activity in those patients missing the gene that produces this protein.
Inovio Pharmaceuticals, Inc. announced today that in a preclinical study with two animal models, Inovio's hTERT (human telomerase reverse transcriptase) DNA cancer vaccine administered with Inovio's CELLECTRA adaptive electroporation delivery technology generated robust and broad immune responses, broke the immune system's tolerance to its self-antigens, induced T-cells with a tumor-killing function, and increased the rate of survival.
Isis Pharmaceuticals, Inc. today announced its financial results for the quarter ended June 30, 2010. The Company finished the second quarter of 2010 with a pro forma net operating loss (NOL) of $15.5 million and $17.1 million for the three and six months ended June 30, 2010, respectively, compared to a pro forma net operating loss of $1.3 million and pro forma net operating income of $798,000 for the same periods of 2009.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Barbara Lubovich, APN, CNM 29373 Network Pl, Chicago, IL 60673-1293 Ph: (847) 390-5900 | Barbara Lubovich, APN, CNM 4400 W 95th St Ste 207, Oak Lawn, IL 60453-2658 Ph: (708) 684-5340 |
News Archive
Diabetes Hands Foundation (DHF) announced today that it is the recipient of two Telly Awards for the diabetes awareness video Big Blue Test.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today results from a long-term efficacy study of Glybera (alipogene tiparvovec) that showed improved chylomicron metabolism could be used as a biomarker for increased lipoprotein lipase (LPL) activity in those patients missing the gene that produces this protein.
Inovio Pharmaceuticals, Inc. announced today that in a preclinical study with two animal models, Inovio's hTERT (human telomerase reverse transcriptase) DNA cancer vaccine administered with Inovio's CELLECTRA adaptive electroporation delivery technology generated robust and broad immune responses, broke the immune system's tolerance to its self-antigens, induced T-cells with a tumor-killing function, and increased the rate of survival.
Isis Pharmaceuticals, Inc. today announced its financial results for the quarter ended June 30, 2010. The Company finished the second quarter of 2010 with a pro forma net operating loss (NOL) of $15.5 million and $17.1 million for the three and six months ended June 30, 2010, respectively, compared to a pro forma net operating loss of $1.3 million and pro forma net operating income of $798,000 for the same periods of 2009.
› Verified 7 days ago
Alyssa M Monsivais, APN-CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 4400 W 95th St Ste 207, Oak Lawn, IL 60453 Phone: 708-684-4636 Fax: 708-684-3045 | |
Kathleen Byrne Cavato, APN Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 5851 W 95th St, Suite 300, Oak Lawn, IL 60453 Phone: 708-499-9800 Fax: 708-499-6203 | |
Christina J Zwit, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 4400 W 95th St Ste 207, Oak Lawn, IL 60453 Phone: 708-684-5340 Fax: 708-684-3371 |